Skip to Content

Ontinua ER Approval Status

FDA Approved: No
Brand name: Ontinua ER
Generic name: arbaclofen
Dosage form: Extended-Release Tablets
Company: Osmotica Pharmaceutical US LLC
Treatment for: Spasticity, Multiple Sclerosis

Ontinua ER (arbaclofen) is a prodrug of R-baclofen in devleopment for the treatment of spasticity associated with multiple sclerosis.

Development Status and FDA Approval Process for Ontinua ER

DateArticle
Sep 28, 2015Osmotica Announces FDA Acceptance of Filing for Ontinua ER for Alleviation of Spasticity Resulting from Multiple Sclerosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide